Studies on sustained contraceptive effects with subcutaneous polydimethylsiloxane implants. 2. Maintenance of ovarian function in patients with megestrol acetate implants.
D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced; D002214:Capsules; D003270:Contraceptive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D003338:Corpus Luteum / Q000254:growth & development; D003692:Delayed-Action Preparations; D004958:Estradiol / Q000652:urine; D004970:Estrone / Q000652:urine; D005260:Female; D005640:Follicle Stimulating Hormone / Q000652:urine; D006801:Humans; D007986:Luteinizing Hormone / Q000652:urine; D008535:Megestrol / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D008598:Menstruation / Q000187:drug effects; D010053:Ovary / Q000187:drug effects; D010060:Ovulation / Q000187:drug effects*; D011276:Pregnanediol / Q000652:urine; D012828:Silicones
D002214:Capsules; D003270:Contraceptive Agents; D003692:Delayed-Action Preparations; D012828:Silicones; D004970:Estrone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008535:Megestrol; D011276:Pregnanediol